Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation
Authors:
- 4 December 2004
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 84 (5) , 321-330
Abstract
We investigated the occurrence of hepatic veno-occlusive disease (VOD) after allogeneic bone marrow transplantation (BMT) in 241 adults conditioned with busulfan + cyclophosphamide at a single institute and retrospectively compared 186 patients who received oral busulfan (O-Bu group) with 55 patients who received intravenous busulfan (I-Bu group). Various hemostatic parameters were determined at baseline and on days 0, 7, 14, and 21. Hepatic VOD occurred in 41.7% of the O-Bu group and in 18.5% of the I-Bu group. Multivariate analysis revealed that the I-Bu group had significantly decreased risk of VOD compared to the O-Bu group [p=0.006, odds ratio: (OR) 0.345]. Eleven patients in the O-Bu group and none of the I-Bu group developed severe VOD. A repeated measures analysis of variance (ANOVA) with a between-subjects factor revealed significant differences in post-transplant levels of antithrombin III, tissue plasminogen activator (tPA), plasminogen activator inhibitor 1 (PAI-1), and D-dimer according to the occurrence of VOD. The level of antithrombin III was significantly lower, whereas the level of D-dimer was significantly higher, in the O-Bu group than in the I-Bu group. These findings show that, in adults conditioned with busulfan + cyclophosphamide, intravenous busulfan was associated with significantly decreased incidence of VOD and fewer hemostatic derangements after allogeneic BMT compared to oral busulfan.Keywords
This publication has 33 references indexed in Scilit:
- Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein ThrombosisNew England Journal of Medicine, 2003
- Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cellsBlood, 2003
- Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortalityTransplantation and Cellular Therapy, 2002
- Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcomeBlood, 2002
- Predictive markers for hepatic veno-occlusive disease after hematopoietic stem cell transplantation in adults: a prospective single center studyBone Marrow Transplantation, 2000
- Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemiaBone Marrow Transplantation, 2000
- Relevance of proteins C and S, antithrombin III, von Willebrand factor, and factor VIII for the development of hepatic veno-occlusive disease in patients undergoing allogeneic bone marrow transplantation: a prospective studyBone Marrow Transplantation, 1998
- Aspects Concerning Busulfan Pharmacokinetics and BioavailabilityLeukemia & Lymphoma, 1996
- Prospective study of endogenous tissue plasminogen activator and risk of strokeThe Lancet, 1994
- Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markersThrombosis Research, 1991